Clinical
RSSArticles
-
Longer Course Therapy for Lyme Disease Is Not Beneficial
A randomized, placebo-controlled clinical trial from the Netherlands found that longer-term antibiotic therapy for Lyme disease did not improve health-related quality of life compared to a standard course of treatment.
-
Predicting Seizure Recurrence with Routine EEG After First Unprovoked Seizure
Using positive likelihood ratios, an adult and child with epileptiform discharges on electroencephalography were estimated to have a 77% and 66% probability, respectively, of recurrent seizures.
-
Too Much of a Good Thing
In the United States in 2010 and 2011, an estimated 30% of outpatient oral antibiotic prescriptions may have been inappropriate, a finding that supports the need for establishing a goal for outpatient antibiotic stewardship.
-
Pioglitazone and Secondary Cardiovascular Prevention
Might a pharmacologic agent that improves insulin resistance be effective in secondary prevention of cardiovascular events?
-
An Infectious Disease Causes Pathological Aggression?
A recent study found that positive Toxoplasma gondii sero-status was statistically significantly associated with aggression.
-
Subclinical Thyroid Disease Associated with Increased Mortality in Seniors
In a population of subjects with subclinical hypothyroidism, a thyroid stimulating hormone > 6.35 mIU/L was the threshold for increasing mortality risk.
-
Two Thumbs Down for COPD Screening
The U.S. Preventive Services Task Force recommends against screening asymptomatic adults for COPD.
-
Improvements in Pain and Physical Function After Bariatric Surgery
Meaningful improvements in physical function and disability due to joint pain occur promptly and are durable through at least three years of follow-up.
-
Glucose Variability in T2DM: Ready for Prime Time?
While not yet a tool for routine practice, analysis of glucose variability appears to hold promise for the future.
-
FDA Actions
Agency approves first biosimilar for infliximab, issues warning about Abilify, announces brand name change for Brintellix, greenlights pimavanserin, and brings to market first generic version of rosuvastatin.